BD Receives 510(k) Clearance for MRSA Diagnostic Artificial Intelligence Software

BD Kiestra™ MRSA Imaging Applications Help Improve Microbiology Laboratory Efficiency and Workflow

franklin lakes, new jersey, May 16, 2023 /PRNewswire/ — BD (Becton, Dickinson & Company) (NYSE:BDX), a global medical technology leader, today received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new BD Kiestra™ methicillin announced that it had acquired – Resistant Staphylococcus aureus An (MRSA) imaging application that uses artificial intelligence (AI) to interpret bacterial growth and release negative analytes with minimal human intervention.

The BD Kiestra™ MRSA application uses AI to automate the traditionally laborious and time-consuming task of inspecting Petri dishes to determine if there is bacterial growth, enabling scientists and technicians in medical laboratories to Frees people to spend more time on higher-value analysis. The application can evaluate single specimens or group large numbers of plates with non-significant gains for batch review and release of negative results, reducing the administrative burden on technicians. can.

The MRSA Imaging application uses AI algorithms to search for specific culture features on BBL™ CHROMagar™ MRSA II plates. Based on that information and analysis by BD Synapsys™ informatics, plate images are automatically organized and grouped into meaningful worklists for lab scientists and technicians.

“The pandemic has created significant and ongoing labor problems in laboratories, and plate reading in microbiology is a labor-intensive and potentially error-prone process,” he said. Nikos Pavlidis, Vice President and General Manager of Diagnostics, BD. “By using this imaging application to automatically organize specimens into meaningful worklists, we are able to make more efficient use of our limited laboratory staff, allowing them to access more important and complex specimens. We will be able to leverage our expertise in

According to the CDC, MRSA in hospital settings can cause serious problems ranging from bloodstream and surgical site infections to sepsis and death. Because laboratory tests are the only way to determine whether a particular type of infection is caused by MRSA, the efficient and effective performance of these tests depends on the patient. can have a significant impact on treatment.

AI-based imaging applications are supported by the BD BBL™ CHROMagar™ MRSA II Screening Plate and BD Synapsys™ Informatics Solution, and can be used on both the standalone BD Kiestra™ ReadA system and track-based BD Kiestra™ Laboratories. automation solution.

BD Kiestra™ solutions provide comprehensive laboratory automation for clinical microbiology laboratories. These solutions are designed to enhance laboratory operations, improve financial efficiency and drive laboratory operations forward. BD Kiestra™ lab automation products include scalable, modular microbial workflow automation solutions ranging from stand-alone units to fully automated track-based automation systems for medium and large labs. Learn more about BD Kiestra here.

BD Synapsys™ Informatics Solution is a lab connectivity and workflow management solution that supports integrated diagnostic processing, automated decision support and on-demand insights to help meet lab challenges and improve outcomes To do. Informatics tools empower lab staff to influence turnaround time, speed decision-making, improve productivity and support compliance requirements. The BD Synapsys™ informatics solution enables laboratories to analyze performance using microbiology informatics through a single advanced platform with an intuitive and personalized user interface. BD Synapsys™ Informatics is the first life to receive Underwriters Laboratory Cybersecurity Assurance Program certification, an independent third-party assessment that uses standardized testable criteria to assess software vulnerabilities and weaknesses. It is one of the science diagnostic information platforms. Learn more about BD Synapsys™

About BD

BD is one of the world’s largest global medical technology companies, advancing the world of health by improving medical discovery, diagnosis and care delivery. The company supports those on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both the clinical care of patients and the clinical process of healthcare providers. BD and its 77,000 employees improve the safety and efficiency of the care delivery process for clinicians, enable laboratory scientists to accurately detect disease, and power the next generation of diagnostics and treatments. I have a passion and commitment to improving the capabilities of researchers to develop. With a presence in nearly every country, BD partners with organizations around the world to tackle some of the toughest global health problems. By working closely with our customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information about BD, please visit bd.com or contact us on LinkedIn (www.linkedin.com/company/bd1/) and Twitter. @BDandCo.

Source BD (Becton, Dickinson and Company)